Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

2 months ago

The success of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro caused the company to hike its guidance. 

More Stories

TSMC and Samsung in talks with UAE to build chip megafactories, WSJ reports

7 mins ago

CNBC Daily Open: Some aren’t convinced of a soft landing

1 hour ago

Rescuers comb muddy riverbanks after floods kill six in Japan

1 hour ago

Leave a Reply

Your email address will not be published. Required fields are marked *

You may have missed

NPFL round-up: Tornadoes, Remo Stars record upset wins

7 mins ago

Police enhance deployment of personnel in Edo to forestall violence

7 mins ago

Silva makes Arsenal trophy dig and appears to mock Gabriel

7 mins ago

UNSEEN ANGLE: New ringside footage of Dubois’ destructive KO of Joshua

7 mins ago

TSMC and Samsung in talks with UAE to build chip megafactories, WSJ reports

7 mins ago